Protagenic Therapeutics, Inc.\new Depreciation & Amortization Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's depreciation and amortization was $49,215 for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $49,215 | — | — |
| 2024 | 2024-12-31 | $50,286 | $22,068 | +78.21% |
| 2023 | 2023-12-31 | $28,218 | $28,188 | +93960.00% |
| 2022 | 2022-12-31 | $30 | $30 | — |
| 2021 | 2021-12-31 | $0 | −$286 | — |
| 2020 | 2020-12-31 | $286 | −$53 | −15.63% |
| 2019 | 2019-12-31 | $339 | −$8 | −2.31% |
| 2018 | 2018-12-31 | $347 | $199 | +134.46% |
| 2017 | 2017-12-31 | $148 | −$386 | −72.28% |
| 2016 | 2016-12-31 | $534 | $391 | +273.43% |
| 2015 · Dec 31 | 2015-12-31 | $143 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $1,000 | $1,000 | — |
| 2014 | 2014-06-30 | $0 | — | — |
Protagenic Therapeutics, Inc.\new quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $8,312 | −$4,259 | −33.88% |
| Q3 2026 | 2025-12-31 | $12,572 | $12,572 | — |
| Q2 2026 | 2025-09-30 | $12,572 | $12,572 | — |
| Q1 2026 | 2025-06-30 | $12,571 | $0 | 0.00% |
| Q4 2025 | 2025-03-31 | $12,572 | $0 | 0.00% |
| Q4 2024 | 2024-12-31 | $0 | — | — |
| Q3 2024 | 2024-09-30 | $0 | −$1,419 | — |
| Q2 2024 | 2024-06-30 | $12,571 | $12,480 | +13714.29% |
| Q1 2024 | 2024-03-31 | $12,572 | $12,482 | +13868.89% |
| Q3 2023 | 2023-09-30 | $1,419 | — | — |
| Q2 2023 | 2023-06-30 | $91 | — | — |
| Q1 2023 | 2023-03-31 | $90 | — | — |
| Q3 2020 | 2020-09-30 | $84 | −$1 | −1.18% |
| Q2 2020 | 2020-06-30 | $81 | −$3 | −3.57% |
| Q1 2020 | 2020-03-31 | $84 | −$1 | −1.18% |
| Q3 2019 | 2019-09-30 | $85 | −$1 | −1.16% |
| Q2 2019 | 2019-06-30 | $84 | −$3 | −3.45% |
| Q1 2019 | 2019-03-31 | $85 | −$4 | −4.49% |
| Q3 2018 | 2018-09-30 | $86 | — | — |
| Q2 2018 | 2018-06-30 | $87 | — | — |
| Q1 2018 | 2018-03-31 | $89 | −$828 | −90.29% |
| Q1 2017 | 2017-03-31 | $917 | $835 | +1018.29% |
| Q3 2016 | 2016-09-30 | $145 | — | — |
| Q2 2016 | 2016-06-30 | $152 | — | — |
| Q1 2016 · Mar 31 | 2016-03-31 | $82 | — | — |
| Q3 2011 · Sep 30 | 2011-09-30 | $233,000 | −$92,000 | −28.31% |
| Q2 2011 | 2011-06-30 | $192,000 | −$132,000 | −40.74% |
| Q3 2011 · Sep 30 | 2010-09-30 | $325,000 | — | — |
| Q2 2010 | 2010-06-30 | $324,000 | — | — |
Protagenic Therapeutics, Inc.\new depreciation and amortization trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's depreciation and amortization increased from $0 to $49,215, a change of $49,215. The latest reported quarter, Q1 2027, shows $8,312.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗